NDAINJECTIONINJECTABLE
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
5/8 — Partial
VERSED (midazolam hydrochloride) by Roche is short-acting benzodiazepine central nervous system (cns) depressant. Approved for atopic dermatitis, advanced solid tumor. First approved in 1985.
Drug data last refreshed Yesterday
Mechanism of Action
short-acting benzodiazepine central nervous system (CNS) depressant.
Worked on VERSED at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.